Skip to main content
EDIT
NASDAQ Life Sciences

Editas Medicine's Edit-401 Shows Preclinical Progress for Hyperlipidemia Treatment

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.93
Mkt Cap
$283.928M
52W Low
$1.345
52W High
$4.537
52W Position info
118% above low
Off High info
35% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

EDIT has more than doubled off its 52-week low of $1.345.

Summary

Editas Medicine announced new preclinical data demonstrating progress for its gene-editing candidate, Edit-401, as a potential treatment for hyperlipidemia. This positive update was presented at the American Society of Gene and Cell Therapy 2026 Annual Meeting. For a small-cap biotech, advancing a pipeline candidate, even at the preclinical stage, is a crucial validation of its technology and future potential. This news provides a positive development on the product front, following recent financial updates from May 5th that highlighted a reduced net loss and extended cash runway. Traders will monitor the progression of Edit-401 towards clinical trials as the next significant catalyst.

At the time of this announcement, EDIT was trading at $2.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $283.9M. The 52-week trading range was $1.35 to $4.54. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

EDIT - Latest Insights

EDIT
Nov 09, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.75
Real-time Price: $2.80 info
Change: +$0.050 (+2%) info
Market Cap: $422.345M info
EDIT
Nov 09, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.61
Real-time Price: $2.80 info
Change: +$0.190 (+7%) info
Market Cap: $422.345M info
EDIT
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $2.61
Real-time Price: $2.80 info
Change: +$0.190 (+7%) info
Market Cap: $422.345M info
EDIT
Oct 08, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.80
Real-time Price: $2.80 info
Change: $0 (0%) info
Market Cap: $422.345M info
EDIT
Oct 08, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.73
Real-time Price: $2.80 info
Change: +$0.070 (+3%) info
Market Cap: $422.345M info